Starke Olivia, Wimberger Pauline, Klotz Daniel Martin
Department of Gynecology and Obstetrics, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany.
National Center for Tumor Diseases/University Cancer Center (NCT/UCC): German Cancer Research Center (DKFZ), Heidelberg, Germany, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Arch Gynecol Obstet. 2025 Jun;311(6):1627-1635. doi: 10.1007/s00404-024-07832-4. Epub 2024 Dec 16.
Ovarian cancer is the fifth most common cancer in women and the leading cause of death of all gynecological malignancies. Prognosis is determined by optimal surgical outcome (macroscopic complete resection) most commonly achieved in tertiary hospitals. We investigated whether tertiary versus non-tertiary hospital as the location of an initial diagnostic intervention for histological confirmation before cytoreductive surgery versus immediate primary debulking surgery impacts outcome in patients with advanced ovarian cancer.
We analyzed 115 patients who underwent cytoreductive surgery at a German tertiary center: 60 patients underwent primary debulking surgery (PDS) and 55 patients had a diagnostic intervention for histological confirmation before debulking surgery (PHC).
Although there was no prognostic difference between the two subgroups, the median time to chemotherapy was longer in the PHC group (46 days) compared to the PDS group (26 days; p < 0.0001), equally seen comparing non-tertiary versus tertiary PHC groups (p: 0.0001), its impact confirmed in a multivariate analysis (PFS: HR: 1.03, 95%CI: 1.01-1.05, p: 0.007; OS: HR: 1.04, 95%CI: 1.02 -1.06, p: < 0.001) of the PHC group only. In total, 9/10 patients with port-site metastases after diagnostic laparoscopy were initially treated at non-tertiary hospitals, resulting in a lower PFS compared to patients without port-site metastases after laparoscopy (HR 0.21, 95%CI 0.06-0.733, p: 0.014).
In conclusion, patients with ovarian cancer undergoing treatment solely at a tertiary center have some clinical benefits and improved outcome, given the shorter time to chemotherapy and potential impact of port-site metastases. This supports centralization of oncological treatment.
卵巢癌是女性中第五大常见癌症,也是所有妇科恶性肿瘤的主要死亡原因。预后取决于最佳手术结果(宏观完全切除),这在三级医院最常实现。我们研究了作为初始诊断干预地点的三级医院与非三级医院,在进行细胞减灭术之前进行组织学确认的诊断干预与立即进行初次肿瘤细胞减灭术相比,对晚期卵巢癌患者的预后是否有影响。
我们分析了在德国一家三级中心接受细胞减灭术的115例患者:60例患者接受了初次肿瘤细胞减灭术(PDS),55例患者在减灭术前进行了组织学确认的诊断干预(PHC)。
虽然两个亚组之间没有预后差异,但PHC组的化疗中位时间(46天)比PDS组(26天)更长(p < 0.0001),非三级与三级PHC组比较也同样如此(p:0.0001),其影响在仅对PHC组的多因素分析中得到证实(无进展生存期:风险比:1.03,95%置信区间:1.01 - 1.05,p:0.007;总生存期:风险比:1.04,95%置信区间:1.02 - 1.06,p:< 0.001)。总共,10例诊断性腹腔镜检查后出现切口转移的患者中有9例最初在非三级医院接受治疗,与腹腔镜检查后无切口转移的患者相比,其无进展生存期更低(风险比0.21,95%置信区间0.06 - 0.733,p:0.014)。
总之,鉴于化疗时间较短以及切口转移的潜在影响,仅在三级中心接受治疗的卵巢癌患者有一些临床益处且预后改善。这支持肿瘤治疗的集中化。